Share

EORTC-EANO Conference 2011: Trends in Central Nervous System Malignancies, Bucharest, Romania, 25-26 March 2011

Following the success of the first EORTC-EANO Conference in 2009 in Hungary, we are extremely proud to announce on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group and the European Association of Neuro-Oncology (EANO), the second in the biennial series of EORTC-EANO Conferences: Trends in Central Nervous System Malignancies.

The main focus of the joint EORTC-EANO Conferences is to progress the neuro-oncology field, accelerate the translation of cutting edge discovery at the clinical level, and further promote international scientific cooperation, debate and exchange.

Adopting a highly multidisciplinary approach, each EORTC-EANO Conference will aim to draw an attendance of neurosurgeons, neurologists, neuropathologists, medical oncologists, and radiation oncologists sharing the common goal of advancing the management, treatment and care of patients with central nervous system tumors, including gliomas, brain and spine metastatic disease, meningioma, CNS lymphoma and primary spinal cord tumors.

Through a series of plenary sessions, workshops and breakout sessions, Trends in Central Nervous System Malignancies will provide a rigorous review of novel therapies, agents and combination strategies, as well as report on the very latest findings in basic and clinical research.

Lastly, but by no means least, our host city Bucharest, known for its wide, tree-lined boulevards, glorious Belle Époque buildings and a reputation for the high life, will provide yet further reason for joining us for the second EORTC-EANO Conference.

We look forward to welcoming you all for what promises to be an outstanding educational event: Trends in Central Nervous System Malignancies, 25-26 March 2011.

Martin J. van den Bent                                    Wolfgang Grisold

EORTC                                                                      EANO

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023